Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1Jacobs syndrome 1Cancer Treatment Induced Thrombocytopenia 1

Interventions

Dexamethasone 64Cyclophosphamide 40Bortezomib 37Melphalan 24Lenalidomide 23Thalidomide 17pomalidomide 16fludarabine 12daratumumab 11carfilzomib 10Filgrastim 8Doxorubicin 8Busulfan 6Prednisone 5Peripheral Blood Stem Cell Transplantation 5Bendamustine Hydrochloride 5selinexor 4sargramostim 4isatuximab 4fludarabine phosphate 4Surveys and Questionnaires 4Etoposide 4Clarithromycin 4Calcium Dobesilate 4liposomal doxorubicin 3ixazomib 3Radiotherapy 3Neoadjuvant Therapy 3Mycophenolic Acid 3Methylprednisolone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Multiple Myeloma × Thrombopoietin × Clear all
NCT02572596 2017-02-09

Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients

Beijing Chao Yang Hospital

Phase NA Unknown
200 enrolled
Plasma cell

Jacobs syndrome, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡